Breast cancer vaccine shows promise in small clinical trial

December 1, 2014 A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients’ immune systems to attack tumor cells and helped slow the cancer’s progression. The study appears Dec. 1 in Clinical Cancer …

AFFiRiS AG has Presented Phase I Data on The Trial for the First Parkinson's Vaccine Candidate

First Clinical Data of Therapeutic Parkinson’s Vaccine is Encouraging

AFFiRiS AG has Presented Phase I Data on a Trial for the First Parkinson’s Vaccine Candidate On the 31st of July 2014, AFFiRiS AG announced as a press conference the results of their phase I clinical trial for a vaccine against Parkinson’s disease.  The vaccine, PD01A, is a therapy that targets the alpha-synuclein protein, a Parkinson’s target. The Michael J.Fox …

If you’re allergic to dust mites (and chances are you are) help may be on the way

Researchers Create Vaccine for Dust-Mite Allergies

If you’re allergic to dust mites (and chances are you are) help may be on the way Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by changing the body’s immune response. In animal tests, the vaccine lowered lung inflammation by 83 percent, according to the paper published in the AAPS (American Association of …

iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology

April 24, 2014 iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines. “The invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins,” said Dr. Wayne Fitzmaurice, iBio’s vice-president of …

iTeos Therapeutics SA Files Patent for Immunomodulators in Cancer Immunotherapy

February 10th, 2014 iTeos Therapeutics SA today announced the filing of the Company’s first patent applications protecting proprietary inhibitors of the intracellular enzyme TDO2, which is expressed at high levels in specific cancers. iTeos Therapeutics has collaborated with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable …

A retrospective look at FierceBiotech’s Top 15 biotechs for 2011

Last September, we posted this blog on The Fierce 15, more specifically, on the 3 biotechs that focused on vaccines.  Looking retrospectively, do you think these 3 will remain a part of the Top 15? What changes do you think will occur?  How far forward have these companies developed in the past year? Take a look below at what was …